Table 1.
Clinical and biochemical parameters of the CAD patients and controls included in studies I and II
| CAD patients Study I (N = 60) | CAD patients Study II (N = 27) | Controls Study II (N = 28) | P* Study II | |
|---|---|---|---|---|
| Age (years) | 65.1 (8.9) | 61 (6.0) | 61 (6.0) | n.s. |
| Male sex, n (%) | 51 (85.0) | 22 (81.4) | 23 (82.1) | n.s. |
| Smoking, n (%) | 5 (8.3) | 13 (48.1) | 9 (32.1) | n.s. |
| Diabetes, n (%) | 11 (18.3) | 1 (3.7) | 1 (3.6) | n.s. |
| Systolic blood pressure (mmHg) | 138 (15) | 136 (21) | 144 (16) | n.s. |
| Diastolic blood pressure (mmHg) | 79 (9) | 80 (10) | 85 (8) | 0.012 |
| Heart rate (beats/min) | 60 (10) | 64 (11) | 71 (13) | 0.041 |
| BMI (kg/m2) | 27.4 (3.3) | 27 (3) | 27 (3) | n.s. |
| Plasma lipids (mmoL/L) | ||||
| Total cholesterol | 3.76 (0.78) | 4.44 (0.78) | 5.89 (0.92) | 6.9 × 10−8 |
| LDL | 1.99 (0.55) | 2.40 (0.63) | 3.80 (0.92) | 4.6 × 10−8 |
| HDL | 1.17 (0.35) | 1.27 (0.33) | 1.38 (0.31) | n.s. |
| TG | 1.39 (0.70) | 1.72 (0.75) | 1.75 (0.91) | n.s. |
| Circulating cell populations (million/dL) | ||||
| Leukocytes | 6.6 (2.1) | 6.4 (1.3) | 6.6 (1.5) | n.s. |
| Neutrophils | 3.7 (1.4) | 3.7 (1.1) | 3.7 (1.1) | n.s. |
| Monocytes | 0.5 (0.2) | 0.7 (0.3) | 0.5 (0.2) | n.s. |
| Lymphocytes | 2.1 (0.9) | 1.9 (0.6) | 2.2 (0.6) | n.s. |
| Medication | ||||
| Statin, n (%) | 59 (98.3) | 25 (92.6) | 3 (10.7) | 3.3 × 10−10 |
| ACE/ARB, n (%) | 42 (70.0) | 13 (48.1) | 3 (10.7) | 0.003 |
| Betablocker, n (%) | 46 (76.7) | 24 (88.9) | 5 (17.9) | 9.9 × 10−8 |
| Calcium channel blockers, n (%) | 21 (35.0) | 4 (14.8) | 3 (10.7) | n.s. |
Continuous variables are presented as mean (SD).
*Comparison between CAD patients and controls in Study II. Student’s T-test was used for continuous variables. The chi-square test or Fischer’s exact test were used to compare categorical variables, as appropriate.